Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis

Launched by UNIVERSITY HOSPITAL OSTRAVA · Apr 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called neoadjuvant stereotactic radiotherapy (NaSRT) for patients with brain metastases, which are cancer cells that have spread to the brain from other parts of the body. The researchers want to see if this method, which involves giving targeted radiation before surgery, can improve outcomes for patients compared to previous studies that only used a single dose of radiation. This study is taking place at four different centers in the Czech Republic and aims to gather more evidence about how effective this approach can be.

To participate in this trial, individuals must be at least 18 years old and have a confirmed primary cancer diagnosis, along with certain MRI findings that show brain metastases suitable for surgical removal. They also need to have a good performance status, meaning they can carry out daily activities with some assistance. However, people with specific conditions, like certain types of blood cancers or those who are pregnant, will not be eligible. Participants can expect to receive radiation treatment and then undergo surgery to remove the targeted brain metastasis within a week. Overall, this trial is important as it seeks to improve treatment options for patients facing brain metastases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Karnofsky Performance Status ≥ 60
• • Histologically verified primary cancer disease
• • MRI findings indicating BM
• • Target BM indicated for surgical resection and any other metastases suitable for radical SRT.
• • Target BM between 1 cm and 7 cm at the longest diameter on T1 post-contrast MR imaging
• Exclusion Criteria:
• • Confirmed hematological malignity
• • Small-cell (lung) carcinoma
• • Peracute condition requiring immediate neurosurgical intervention
• • History of whole-brain radiotherapy (WBRT)
• • History of stereotactic radiotherapy to a target brain metastasis
• • Pregnancy
• • Inability to perform surgical resection of the target BM within 7 days after NaSRT